Back to top
more

ChromaDex (CDXC)

(Delayed Data from NSDQ)

$3.19 USD

3.19
376,379

-0.01 (-0.31%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CDXC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

ChromaDex Corporation [CDXC]

Reports for Purchase

Showing records 81 - 100 ( 117 total )

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 81

08/07/2018

Company Report

Pages: 4

Watsons Retail Partnership on TRU NIAGEN Extended and Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 82

07/16/2018

Company Report

Pages: 4

New Human Data May Indicate Role for NIAGEN in Enhancing Liver Health; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 83

06/05/2018

Company Report

Pages: 4

Chief Marketing Officer Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 84

05/14/2018

Company Report

Pages: 4

1Q 2018 Results Reported; Top-Line In-Line; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 85

05/07/2018

Company Report

Pages: 4

Inter Partes Review Trial; Management Changes Effected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 86

04/02/2018

Company Report

Pages: 4

Clinical Trial Data Underscore NIAGEN Health Benefits; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 87

03/09/2018

Company Report

Pages: 3

4Q and FY2017 Results Reported; Revenue In-Line; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 88

03/05/2018

Company Report

Pages: 4

Preliminary 2017 Guidance; Modulating Forward Projections; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 89

02/09/2018

Company Report

Pages: 4

More Preclinical Alzheimer''s Model Data Indicates Role for NIAGEN; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 90

01/23/2018

Company Report

Pages: 4

Favorable Patent Ruling on Flagship Product; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 91

01/16/2018

Company Report

Pages: 4

Watsons Partnership Begins Bearing Fruit; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 92

12/15/2017

Company Report

Pages: 4

Nicotinamide Riboside Potential in Neurological and Cardiac Diseases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 93

11/27/2017

Company Report

Pages: 5

3Q17 Financial Results Reported; Further Strategic Investment; Raising Price Target to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 94

10/02/2017

Company Report

Pages: 4

Second Human Clinical Trial Reports Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 95

09/11/2017

Company Report

Pages: 5

Watsons Partnership Opens Door to Asia; Reiterate Buy and Raising Price Target to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 96

08/11/2017

Company Report

Pages: 5

2Q 2017 Financial Results Reported; Revenue Light; Reducing Price Target

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 97

08/11/2017

Company Report

Pages: 5

2Q 2017 Financial Results Reported; Revenue Light; Reducing Price Target

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 98

03/20/2017

Company Report

Pages: 4

4Q and FY2016 Results Reported; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 99

03/20/2017

Company Report

Pages: 4

4Q and FY2016 Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: ChromaDex Corporation

Industry: Medical - Biomedical and Genetics

Record: 100

02/27/2017

Company Report

Pages: 4

Nicotinamide Riboside Activity in Peripheral Neuropathy; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party